<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65587">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02056938</url>
  </required_header>
  <id_info>
    <org_study_id>RC14_0051</org_study_id>
    <nct_id>NCT02056938</nct_id>
  </id_info>
  <brief_title>ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF</brief_title>
  <acronym>PREDICT-DGF</acronym>
  <official_title>Prospective Multicentric, Randomized, Open-labeled, in Parallel Groups, Study to Assess the Benefit/Risk of an Induction Treatment With Anti-Thymocyte Globulins (ATG) Versus Basiliximab in Kidney Transplant Patients Displaying Low Immunological Risk But High Susceptibility to Delayed Graft Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France-':ANSM'</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the following randomized open label trial is to  demonstrate how
      low immunological risk patients (no anti HLA immunization and first kidney transplantation)
      but diagnosed at high-risk of delayed graft function (assessed by DGFS score) could benefit
      from induction with ATG for preventing delayed graft function compared to Basiliximab.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Occurrence of a delayed graft function</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Occurrence of a delayed graft function defined as the need for dialysis within the first seven days post transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the delayed graft function</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of the DGF defined by the number of days after the transplantation to reach an estimated glomerular filtration rate (eGFR) above 10 mL/min. Only eGFR assessments at least 48 hours after the last day of dialysis will be considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evolution of eGFR from day 1 to day 7 post transplantation then every two days until hospital discharge. Only eGFR assessments at least 48 hours after the last day of dialysis will be considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dialysis procedures performed after transplantation without taking into account the dialysis due to hyperkaliemia and/or hyperhydratation</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Tacrolimus levels (T0) from Day 1 to Day 7 post transplantation then every 2 days until hospital discharge.</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic effect within the first 3 months of surgery (WBC monitoring, CD3, CD4, CD8, CD19, NK and platelet sub population analysis).</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of infections within the first 3 months post transplantation, especially the CMV and BK reactivation assessed by RTPCR</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of biopsy-confirmed acute rejection episodes and subclinical acute rejection episodes within the first 3 months post transplantation.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of renal fibrosis on a surveillance kidney biopsy at 3 months post transplantation</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of renal fibrosis on a surveillance kidney biopsy at 3 months post transplantation will be evaluated by computerized quantification.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first infusion of Thymoglobuline® begins before the kidney reperfusion. In case of a patient with a functional arteriovenous fistula or a high-flow venous catheter, the infusion of Thymoglobuline® can begin just after the randomization pre operatively. When the patient has no available arteriovenous fistula for the Thymoglobuline® infusion, it is necessary to install a high-flow vein (central vein) by the anesthesiologist, and to begin the perfusion as soon as possible intra-operatively before the reperfusion of the kidney. The dose of Thymoglobuline® per infusion is 1.5mg/kg. The duration of each infusion is between 6 to 24 hours.
The total duration of the Thymoglobuline® administration is 4 days (starting at and including the first day of the surgery).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basiliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The first infusion of Simulect® begins post-surgery. There is no need of central venous catheter or arteriovenous fistula to infuse the Simulect®. The duration of the infusion is 30 minutes. Each dose of Simulect® is 20 mg. The first infusion of Simulect® is displayed on Day 0 (began just after the surgery) and the second infusion 3 days afterward.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Thymocyte Globulins treatment</intervention_name>
    <arm_group_label>ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab treatment</intervention_name>
    <arm_group_label>Basiliximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults

          -  First kidney transplantation

          -  No anti HLA immunization prior transplantation

          -  A risk of DGF higher than 50% calculated by the score DGFS (DGFS &gt;= 1.2)

          -  Written informed consent

        Exclusion Criteria:

          -  Previous or combined other transplantations

          -  Non heart beating donors

          -  Living donors

          -  Pre-emptive transplantation

          -  Patients on peritoneal dialysis

          -  Leucopenia lower than 3000/mm3

          -  Thrombopenia lower than 100 000/mm3

          -  Donor EBV positive / recipient EBV Negative

          -  Pregnant or lactating women

          -  Patients under guardianship

          -  Previous and current history of cancer and/or lymphoma

          -  Current history of HCV or HBV or HIV infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magali GIRAL, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes universitary hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magali GIRAL, Professor</last_name>
    <phone>+33 2 40 08 74 43</phone>
    <email>mgiral@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion CHAPAL, Doctor</last_name>
    <phone>+33 2 40 08 74 08</phone>
    <email>marion.chapal@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitary hospital of Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel MORELON, Professor</last_name>
      <phone>+33 4 72 11 01 78</phone>
      <email>emmanuel.morelon@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel MORELON, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitary hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georges MOURAD, Professor</last_name>
      <phone>+33 4 67 33 84 76</phone>
      <email>g-mourad@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Georges MOURAD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes Universitary hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magali GIRAL, Professor</last_name>
      <phone>+33 2 40 08 74 43</phone>
      <email>mgiral@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marion CHAPAL, Doctor</last_name>
      <phone>+33 2 40 08 74 08</phone>
      <email>marion.chapal@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Magali GIRAL, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion CHAPAL, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitary hospital of Nice</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth CASSUTO, Doctor</last_name>
      <phone>+33 4 92 03 77 36</phone>
      <email>cassuto.e@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth CASSUTO, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe LEGENDRE, Professor</last_name>
      <phone>+33 1 44 49 53 55</phone>
      <email>christophe.legendre@nck.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe LEGENDRE, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitary Hospital of Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc LADRIERE, Doctor</last_name>
      <phone>+33 3 83 15 31 69</phone>
      <email>m.ladriere@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Marc LADRIERE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplantation</keyword>
  <keyword>kidney</keyword>
  <keyword>delayed graft function</keyword>
  <keyword>induction therapy</keyword>
  <keyword>personalized medicine</keyword>
  <keyword>First kidney transplantation</keyword>
  <keyword>No anti HLA immunization prior transplantation</keyword>
  <keyword>Risk of DGF higher than 50% calculated byt he score DGFS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Delayed Graft Function</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
